Abiopharma

🔍 Ring Christine (Executive)

Company: Nurix Therapeutics, Inc. (NRIX)

Report Date: 2026-08-03

Detailed Transactions and Holdings:

• Acquired 5,787 shares of Common Stock at $8.72 per share (Direct)
  Date: 2026-08-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 25,699.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 16,589 shares of Common Stock at $23.0489 per share (Direct)
  Date: 2026-08-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 9,110.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 5,787 shares of Employee Stock Option (right to buy) at $8.72 per share (Derivative)
  Date: 2026-08-03 | Code: M | Expires: 2034-02-12 | equity_swap_involved: 0 | shares_owned_after: 122,824.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
• F2: Represents the weighted average sale price. The lowest price at which shares were sold was $22.67 and the highest price at which shares were sold was $23.30. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
• F3: The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.